AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
sulbactam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| beta-lactamase inhibitors | 2492 | 68373-14-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A beta-lactamase inhibitor with very weak antibacterial action. The compound prevents antibiotic destruction of beta-lactam antibiotics by inhibiting beta-lactamases, thus extending their spectrum activity. Combinations of sulbactam with beta-lactam antibiotics have been used successfully for the therapy of infections caused by organisms resistant to the antibiotic alone.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 285.97 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 0.32 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 5.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.62 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.10 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -2.053 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 3.664 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.265 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 2.871 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 70.670 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 55.160 | % | High | 1 |
| herg | hERG pIC50 | 4.767 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.186 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 4.467 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 51.210 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 52 | |||
| kinase-selectivity-class | ACVR2B,AXL,CDK9,EIF2AK3,GRK2,MAP2K6,TEK,TGFBR1 | 8 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.653 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 3.327 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 74.910 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.379 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 63.470 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 2.280 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 93.230 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 43.480 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 807.235 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 31, 1986 | FDA | PFIZER |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Enterocolitis haemorrhagic | 70.58 | 26.94 | 14 | 1739 | 1718 | 90624976 |
| Hepatic function abnormal | 59.30 | 26.94 | 25 | 1728 | 46263 | 90580431 |
| Culture stool positive | 41.94 | 26.94 | 7 | 1746 | 327 | 90626367 |
| Stevens-Johnson syndrome | 34.73 | 26.94 | 15 | 1738 | 29361 | 90597333 |
| Klebsiella infection | 33.36 | 26.94 | 11 | 1742 | 10286 | 90616408 |
| Toxic epidermal necrolysis | 33.26 | 26.94 | 15 | 1738 | 32513 | 90594181 |
| Epidermolysis | 30.51 | 26.94 | 6 | 1747 | 703 | 90625991 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Kidney duplex | 64.67 | 21.63 | 12 | 2088 | 399 | 42618836 |
| Cardiac septal defect | 54.52 | 21.63 | 12 | 2088 | 948 | 42618287 |
| Enterocolitis haemorrhagic | 42.34 | 21.63 | 10 | 2090 | 1081 | 42618154 |
| Hepatic function abnormal | 39.50 | 21.63 | 27 | 2073 | 51540 | 42567695 |
| Interstitial lung disease | 25.64 | 21.63 | 25 | 2075 | 78437 | 42540798 |
| Pyrexia | 24.15 | 21.63 | 57 | 2043 | 393985 | 42225250 |
| Aspartate aminotransferase increased | 22.29 | 21.63 | 23 | 2077 | 77140 | 42542095 |
| Respiratory failure | 21.65 | 21.63 | 29 | 2071 | 128103 | 42491132 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Enterocolitis haemorrhagic | 108.34 | 23.24 | 23 | 3234 | 2581 | 110583461 |
| Hepatic function abnormal | 77.24 | 23.24 | 42 | 3215 | 89253 | 110496789 |
| Culture stool positive | 46.03 | 23.24 | 9 | 3248 | 669 | 110585373 |
| Aspartate aminotransferase increased | 38.05 | 23.24 | 34 | 3223 | 159902 | 110426140 |
| Stevens-Johnson syndrome | 34.89 | 23.24 | 20 | 3237 | 46881 | 110539161 |
| Toxic epidermal necrolysis | 31.37 | 23.24 | 20 | 3237 | 56707 | 110529335 |
| Alanine aminotransferase increased | 28.62 | 23.24 | 31 | 3226 | 183742 | 110402300 |
| Respiratory failure | 26.24 | 23.24 | 32 | 3225 | 215300 | 110370742 |
| Interstitial lung disease | 26.18 | 23.24 | 26 | 3231 | 139308 | 110446734 |
| Pneumonia | 25.94 | 23.24 | 70 | 3187 | 876644 | 109709398 |
| Epidermolysis | 24.96 | 23.24 | 6 | 3251 | 1172 | 110584870 |
| Klebsiella infection | 24.77 | 23.24 | 12 | 3245 | 19997 | 110566045 |
| Rash | 24.73 | 23.24 | 66 | 3191 | 820898 | 109765144 |
| Sepsis | 23.89 | 23.24 | 38 | 3219 | 327308 | 110258734 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01CG01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Beta-lactamase inhibitors |
| ATC | J01CG30 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Beta-lactamase inhibitors |
| FDA MoA | N0000000202 | beta Lactamase Inhibitors |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D065093 | beta-Lactamase Inhibitors |
| FDA EPC | N0000175930 | beta Lactamase Inhibitor |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
Related Drugs by ATC class:
J01CG Beta-lactamase inhibitors 2 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
| Infection due to Escherichia coli | indication | 71057007 | |
| Rhinoscleroma | indication | 72409005 | DOID:11336 |
| Cholangitis | indication | 82403002 | DOID:9446 |
| Female genital tract infection | indication | 125585007 | |
| Infectious disease of abdomen | indication | 128070006 | |
| Infection due to Enterobacteriaceae | indication | 128945009 | |
| Bacterial peritonitis | indication | 197171003 | |
| Infection due to Staphylococcus aureus | indication | 406602003 | |
| Ventilator-associated bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex | indication | 429271009 | |
| Infection caused by carbapenem-resistant acinetobacter baumannii-calcoaceticus complex | indication | 445780006 | |
| Hospital-acquired bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex | indication | 1010634002 | |
| Intra-Abdominal E. Coli Abscess | indication | ||
| E. Coli Peritonitis | indication | ||
| Skin and Skin Structure Acinetobacter Infection | indication | ||
| E. Coli Gynecological Infections | indication | ||
| Klebsiella Pneumoniae Peritonitis | indication | ||
| Skin and Skin Structure Bacteroides Fragilis Infection | indication | ||
| Bacteroides Gynecological Infections | indication | ||
| Inflammatory Disease of Female Pelvic Organs | indication | ||
| Bacteroides Peritonitis | indication | ||
| Skin and Skin Structure Proteus Infection | indication | ||
| Streptococcal meningitis | off-label use | 4510004 | DOID:11574 |
| Pyrexia of unknown origin | off-label use | 7520000 | |
| Bacterial pneumonia | off-label use | 53084003 | DOID:874 |
| Infection of bone | off-label use | 111253001 | |
| Meningococcal meningitis | off-label use | 192644005 | |
| Sepsis of the newborn | off-label use | 206376005 | |
| Human bite - wound | off-label use | 262555007 | |
| Diverticulitis of gastrointestinal tract | off-label use | 271366000 | |
| Neonatal meningitis | off-label use | 276674008 | |
| Dog bite - wound | off-label use | 283734005 | |
| Cat bite - wound | off-label use | 283782004 | |
| Infective otitis media | off-label use | 312218008 | |
| Diabetic Foot Infection | off-label use | ||
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Infectious mononucleosis | contraindication | 271558008 | DOID:8568 |
| Pseudomembranous enterocolitis | contraindication | 397683000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.1 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL | XACDURO (COPACKAGED) | ENTASIS THERAP | N216974 | May 23, 2023 | RX | POWDER | INTRAVENOUS | 9623014 | April 2, 2033 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) |
| EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL | XACDURO (COPACKAGED) | ENTASIS THERAP | N216974 | May 23, 2023 | RX | POWDER | INTRAVENOUS | 10376499 | Nov. 17, 2035 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) |
| EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL | XACDURO (COPACKAGED) | ENTASIS THERAP | N216974 | May 23, 2023 | RX | POWDER | INTRAVENOUS | 9968593 | Nov. 17, 2035 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL | XACDURO (COPACKAGED) | ENTASIS THERAP | N216974 | May 23, 2023 | RX | POWDER | INTRAVENOUS | May 23, 2028 | NEW CHEMICAL ENTITY |
| EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL | XACDURO (COPACKAGED) | ENTASIS THERAP | N216974 | May 23, 2023 | RX | POWDER | INTRAVENOUS | May 23, 2033 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Serine beta-lactamase-like protein LACTB, mitochondrial | Enzyme | IC50 | 5.01 | WOMBAT-PK | |||||
| Beta-lactamase TEM | Enzyme | INHIBITOR | Ki | 6.10 | CHEMBL | CHEMBL | |||
| Beta-lactamase | Enzyme | IC50 | 5.19 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 4.18 | CHEMBL | |||||
| Beta-lactamase SHV-1 | Enzyme | IC50 | 5.41 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 6 | CHEMBL | |||||
| Beta-lactamase OXA-1 | Enzyme | IC50 | 4.66 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 4.57 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 5.21 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 7.12 | CHEMBL | |||||
| Carbapenem-hydrolizing beta-lactamase SFC-1 | Enzyme | IC50 | 4.64 | CHEMBL | |||||
| Beta-lactamase GES-13 | Enzyme | IC50 | 6.43 | CHEMBL | |||||
| Class D beta-lactamase | Enzyme | IC50 | 4.92 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 5.62 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 5.95 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 5.11 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 5.40 | CHEMBL | |||||
| Beta-lactamase TEM | Enzyme | Ki | 6.10 | WOMBAT-PK | |||||
| ADC-18 protein | Enzyme | IC50 | 4.93 | CHEMBL | |||||
| Beta-lactamase 1 | Enzyme | IC50 | 4.60 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 5.52 | CHEMBL | |||||
| Beta-lactamase | Enzyme | IC50 | 5.52 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019937 | VUID |
| N0000148022 | NUI |
| D02223 | KEGG_DRUG |
| 69388-84-7 | SECONDARY_CAS_RN |
| 4019381 | VANDF |
| 4019937 | VANDF |
| C0038665 | UMLSCUI |
| CHEBI:9321 | CHEBI |
| 0RN | PDB_CHEM_ID |
| CHEMBL403 | ChEMBL_ID |
| DB09324 | DRUGBANK_ID |
| CHEMBL1200944 | ChEMBL_ID |
| D013407 | MESH_DESCRIPTOR_UI |
| 130313 | PUBCHEM_CID |
| 10769 | IUPHAR_LIGAND_ID |
| 4845 | INN_ID |
| S4TF6I2330 | UNII |
| 10167 | RXNORM |
| 5520 | MMSL |
| d04403 | MMSL |
| 002811 | NDDF |
| 002812 | NDDF |
| 398916003 | SNOMEDCT_US |
| 412516007 | SNOMEDCT_US |
| 96008003 | SNOMEDCT_US |
| S4TF6I2330 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| UNASYN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0049-0013 | INJECTION, POWDER, FOR SOLUTION | 0.50 g | INTRAMUSCULAR | NDA | 25 sections |
| UNASYN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0049-0014 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | NDA | 25 sections |
| UNASYN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0049-0024 | INJECTION, POWDER, FOR SOLUTION | 50 mg | INTRAMUSCULAR | NDA | 25 sections |
| UNASYN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0049-0710 | INJECTION, POWDER, FOR SOLUTION | 0.50 g | INTRAMUSCULAR | NDA | 25 sections |
| UNASYN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0049-1515 | INJECTION, POWDER, FOR SOLUTION | 50 mg | INTRAMUSCULAR | NDA | 25 sections |
| UNASYN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0049-3003 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | NDA | 25 sections |
| Ampicillin and Sulbactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-2689 | INJECTION, POWDER, FOR SOLUTION | 0.50 g | INTRAVENOUS | ANDA | 25 sections |
| Ampicillin and Sulbactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0409-2987 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 25 sections |
| Ampicillin and Sulbactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0641-6116 | INJECTION, POWDER, FOR SOLUTION | 0.50 g | INTRAVENOUS | ANDA | 24 sections |
| Ampicillin and Sulbactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0641-6117 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 24 sections |
| Ampicillin and Sulbactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0641-6118 | INJECTION, POWDER, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 24 sections |
| ampicillin and sulbactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 25021-142 | INJECTION, POWDER, FOR SOLUTION | 0.50 g | INTRAVENOUS | ANDA | 26 sections |
| ampicillin and sulbactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 25021-143 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 26 sections |
| ampicillin and sulbactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 25021-144 | INJECTION, POWDER, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 25 sections |
| Ampicillin and Sulbactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 36000-094 | INJECTION, POWDER, FOR SOLUTION | 0.50 g | INTRAVENOUS | ANDA | 26 sections |
| Ampicillin and Sulbactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 36000-095 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 26 sections |
| Ampicillin and Sulbactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 44567-150 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 23 sections |
| Ampicillin and Sulbactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 44567-210 | INJECTION, POWDER, FOR SOLUTION | 0.50 g | INTRAVENOUS | ANDA | 23 sections |
| Ampicillin and Sulbactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 44567-211 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 23 sections |
| Ampicillin and Sulbactam | HUMAN PRESCRIPTION DRUG LABEL | 2 | 44567-212 | INJECTION, POWDER, FOR SOLUTION | 5 g | INTRAVENOUS | ANDA | 21 sections |
| Ampicillin and Sulbactam | Human Prescription Drug Label | 2 | 55150-116 | INJECTION, POWDER, FOR SOLUTION | 0.50 g | INTRAMUSCULAR | ANDA | 23 sections |
| Ampicillin and Sulbactam | Human Prescription Drug Label | 2 | 55150-116 | INJECTION, POWDER, FOR SOLUTION | 0.50 g | INTRAMUSCULAR | ANDA | 23 sections |
| Ampicillin and Sulbactam | Human Prescription Drug Label | 2 | 55150-116 | INJECTION, POWDER, FOR SOLUTION | 0.50 g | INTRAMUSCULAR | ANDA | 23 sections |
| Ampicillin and Sulbactam | Human Prescription Drug Label | 2 | 55150-117 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 23 sections |
| Ampicillin and Sulbactam | Human Prescription Drug Label | 2 | 55150-117 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 23 sections |
| Ampicillin and Sulbactam | Human Prescription Drug Label | 2 | 55150-117 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 23 sections |
| Ampicillin and Sulbactam | Human Prescription Drug Label | 2 | 55150-118 | INJECTION, POWDER, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 23 sections |
| Ampicillin and Sulbactam | Human Prescription Drug Label | 2 | 55150-118 | INJECTION, POWDER, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 23 sections |
| Ampicillin and Sulbactam | Human Prescription Drug Label | 2 | 55150-118 | INJECTION, POWDER, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 23 sections |
| Ampicillin and Sulbactam | Human Prescription Drug Label | 2 | 55150-178 | INJECTION, POWDER, FOR SOLUTION | 0.50 g | INTRAVENOUS | ANDA | 23 sections |